Literature DB >> 16935750

The development of molecular clamps as drugs.

Stephanie T Weiss1, Neil R McIntyre, Mark L McLaughlin, David J Merkler.   

Abstract

Some enzymes catalyze the modification of an ensemble of substrates in vivo and, as a consequence, are not ideal targets for active-site-directed drugs. One solution to inhibiting such multisubstrate enzymes would be a drug that binds tightly to only one substrate, which prevents the binding of that substrate to the enzyme. Ideally, such a drug (called a molecular clamp, a molecular forcep or a molecular tweezer) would prevent the enzymatic processing of only the targeted substrate. This would enable the enzyme to function normally on all other substrates. Here, we review the unique steady-state kinetic features of molecular clamp inhibition, identify potential targets for molecular clamp inhibition, and discuss problems for the therapeutic use of molecular clamps.

Mesh:

Substances:

Year:  2006        PMID: 16935750     DOI: 10.1016/j.drudis.2006.07.011

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  3 in total

Review 1.  Intrinsically disordered proteins are potential drug targets.

Authors:  Steven J Metallo
Journal:  Curr Opin Chem Biol       Date:  2010-07-02       Impact factor: 8.822

Review 2.  Peptidylglycine α-amidating monooxygenase as a therapeutic target or biomarker for human diseases.

Authors:  David J Merkler; Aidan J Hawley; Betty A Eipper; Richard E Mains
Journal:  Br J Pharmacol       Date:  2022-02-28       Impact factor: 9.473

3.  AβPP-selective BACE inhibitors (ASBI): novel class of therapeutic agents for alzheimer's disease.

Authors:  Olivier Descamps; Patricia Spilman; Qiang Zhang; Clare P Libeu; Karen Poksay; Olivia Gorostiza; Jesus Campagna; Barbara Jagodzinska; Dale E Bredesen; Varghese John
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.